Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the interaction of this domain with the FXa active site. Injections of Concizumab increase thrombin in the blood and can be used to prevent and treat hemophilia.